Cathy Moelans

Dr. Cathy Moelans

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
CMCathy Moelans
Cathy Moelans
AVAnoek Hj Verschuur‐Maes
Anoek Hj Verschuur‐Maes
PDPaul J van Diest
Paul J van Diest

1 December 2011 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CMCathy Moelans
Cathy Moelans
RWR.A. de Weger
R.A. de Weger
EWE. Van der Wall
E. Van der Wall
PDP.J. van Diest
P.J. van Diest

18 September 2009 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
CMCathy Moelans
Cathy Moelans
RWRoel A. de Weger
Roel A. de Weger
PDPaul J. van Diest
Paul J. van Diest
Amplification of the HER2 gene, present in 15–30% of breast carcinomas, correlates with poor outcome and is an indication for treatment with trastuzumab. Standard testing methods for HER2 amplification are fluorescence (FISH) or chromogenic in situ hybridization (CISH). In FISH/CISH scoring, correction for chromosome 17 polysomy is believed to be critical for determination of true HER2 amplification as opposed to increased chromosome 17 copy number. The term “polysomy 17” is widely used and defined as ≥3 copies of the chromosome 17 centromere (probe CEP17, D17Z1). Thus, the centromere is assumed to be representative for the entire chromosome. This study aimed to investigate the frequency of polysomy 17 and its association with HER2 amplification in 111 invasive breast cancer patients by CEP17 CISH and by copy number analysis of a set of 17 genes along chromosome 17 using multiplex ligation-dependent probe amplification (MLPA). Chromosome 17 usually showed a complex pattern of gains and losses by MLPA, unrelated to the copy number status of the centromere. Increase in centromere 17 copy number (denoted “polysomy 17”), as assessed by CEP17 CISH, was found in 19% of the patients. Of these patients, 60% also showed amplification of HER2 measured by MLPA. However, none of the 111 patients showed a true polysomy of chromosome 17 by MLPA. Only two patients (1.8%) had a possible gain of 17q. Amplification of 17p was not found in any of the patients, although a possible loss of 17p was found in one patient. In conclusion, this extensive analysis of amplicons along chromosome 17 shows that true polysomy of chromosome 17, either of the whole chromosome or of the short or the long arm, is very rare in invasive breast cancer. Abnormal CEP17 copy numbers may therefore actually stem from high level gains or amplification of CEP17 regardless of copy number gains of the short and long arms of chromosome 17 and, at least in some cases, correction with CEP17 probes may provide misleading HER2 gene status assessment results.

13 March 2012 in Cancer
Verified
Journal Article
Open access
PDF file
LHLaurien D. C. Hoefnagel
Laurien D. C. Hoefnagel
CMCathy Moelans
Cathy Moelans
SMS. L. Meijer
S. L. Meijer
HSHenk‐Jan van Slooten
Henk‐Jan van Slooten
PWPieter Wesseling
Pieter Wesseling
PDPaul J van Diest
Paul J van Diest
BACKGROUND: Changes in the receptor profile of primary breast cancers to their metastases (receptor conversion) have been described for the estrogen receptor α (ERα) and progesterone receptor (PR). The purpose of this study was to evaluate the impact of receptor conversion for ERα and PR on survival in a large group of distant non‐bone breast cancer metastases.METHODS: Receptor conversion was studied by immunohistochemistry in a group of 233 metastatic breast cancer patients. Kaplan‐Meier overall survival curves were plotted, and differences between the curves were analyzed by log‐rank analysis. The additional prognostic value of conversion to established prognosticators was studied by Cox regression.RESULTS: Overall survival of patients showing conversion from positive to negative ERα or PR, or from negative to positive ERα or PR, or remaining receptor negative was comparable, and significantly worse than patients remaining receptor positive. ERα or PR receptor conversion from positive in the primary breast tumor to negative in distant metastases has independent negative prognostic value.CONCLUSIONS: ERα or PR receptor conversion from positive in the primary breast cancer to negative in distant metastases has negative prognostic value. Cancer 2012. © 2012 American Cancer Society.

1 July 2010 in Laboratory Investigation
Verified
Journal Article
Closed access
CMCathy Moelans
Cathy Moelans
RWRoel A de Weger
Roel A de Weger
HMHanneke N Monsuur
Hanneke N Monsuur
RVRaymon Vijzelaar
Raymon Vijzelaar
PDPaul J van Diest
Paul J van Diest

3 December 2018 in eLife
Verified
Journal Article
Open access
SVStephin J Vervoort
Stephin J Vervoort
OJOlivier G de Jong
Olivier G de Jong
MRM Guy Roukens
M Guy Roukens
CFCynthia L Frederiks
Cynthia L Frederiks
JVJeroen F Vermeulen
Jeroen F Vermeulen
PCPaul J Coffer
Paul J Coffer
The expression of the transcription factor SOX4 is increased in many human cancers, however, the pro-oncogenic capacity of SOX4 can vary greatly depending on the type of tumor. Both the contextual nature and the mechanisms underlying the pro-oncogenic SOX4 response remain unexplored. Here, we demonstrate that in mammary tumorigenesis, the SOX4 transcriptional network is dictated by the epigenome and is enriched for pro-angiogenic processes. We show that SOX4 directly regulates endothelin-1 (ET-1) expression and can thereby promote tumor-induced angiogenesis both in vitro and in vivo. Furthermore, in breast tumors, SOX4 expression correlates with blood vessel density and size, and predicts poor-prognosis in patients with breast cancer. Our data provide novel mechanistic insights into context-dependent SOX4 target gene selection, and uncover a novel pro-oncogenic role for this transcription factor in promoting tumor-induced angiogenesis. These findings establish a key role for SOX4 in promoting metastasis through exploiting diverse pro-tumorigenic pathways.